Share on StockTwits

ISIS Pharmaceuticals (NASDAQ:ISIS) Director Frederick T. Muto sold 10,000 shares of the company’s stock on the open market in a transaction dated Monday, June 2nd. The stock was sold at an average price of $28.59, for a total value of $285,900.00. Following the completion of the transaction, the director now directly owns 313 shares in the company, valued at approximately $8,949. The sale was disclosed in a legal filing with the SEC, which is available at this link.

A number of research firms have recently commented on ISIS. Analysts at Summer Street reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Friday, May 23rd. Separately, analysts at TheStreet downgraded shares of ISIS Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, May 8th. Finally, analysts at JPMorgan Chase & Co. reiterated a “neutral” rating on shares of ISIS Pharmaceuticals in a research note on Wednesday, May 7th. They now have a $38.00 price target on the stock, down previously from $59.00. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have given a buy rating to the stock. The company currently has an average rating of “Hold” and an average price target of $41.70.

ISIS Pharmaceuticals (NASDAQ:ISIS) traded down 2.66% during mid-day trading on Tuesday, hitting $27.77. 1,900,920 shares of the company’s stock traded hands. ISIS Pharmaceuticals has a one year low of $20.52 and a one year high of $62.66. The stock has a 50-day moving average of $28.47 and a 200-day moving average of $40.29. The company’s market cap is $3.265 billion.

ISIS Pharmaceuticals (NASDAQ:ISIS) last released its earnings data on Tuesday, May 6th. The company reported ($0.27) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.23) by $0.04. The company had revenue of $28.20 million for the quarter, compared to the consensus estimate of $35.12 million. During the same quarter in the prior year, the company posted ($0.02) earnings per share. The company’s quarterly revenue was down 35.0% on a year-over-year basis. Analysts expect that ISIS Pharmaceuticals will post $-0.71 EPS for the current fiscal year.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.